Loss of RAB39B Does Not Alter MPTP-induced Parkinson’s Disease-Like Phenotypes in Mice

Zijie Wang,Dingting Yang,Yiru Jiang,Yong Wang,Mengxi Niu,Chong Wang,Hong Luo,Huaxi Xu,Jingwen Li,Yun-wu Zhang,Xian Zhang

DOI: https://doi.org/10.3389/fnagi.2023.1087823

IF: 4.8

2023-01-01

Frontiers in Aging Neuroscience

Abstract:Parkinson’s disease (PD) is a common neurodegenerative movement disorder with undetermined etiology. A major pathological hallmark of PD is the progressive degeneration of dopaminergic neurons in the substantia nigra. Loss-of-function mutations in the RAB39B gene, which encodes a neuronal-specific small GTPase RAB39B, have been associated with X-linked intellectual disability and pathologically confirmed early-onset PD in multiple families. However, the role of RAB39B in PD pathogenesis remains elusive. In this study, we treated Rab39b knock-out (KO) mice with MPTP to explore whether RAB39B deficiency could alter MPTP-induced behavioral impairments and dopaminergic neuron degeneration. Surprisingly, we found that MPTP treatment impaired motor activity and led to loss of tyrosine hydroxylase-positive dopaminergic neurons and gliosis in both WT and Rab39b KO mice. However, RAB39B deficiency did not alter MPTP-induced impairments. These results suggest that RAB39B deficiency does not contribute to PD-like phenotypes through compromising dopaminergic neurons in mice; and its role in PD requires further scrutiny.